% 112.68 99.26 14% Earnings before interest tax and deprecation 114.01 80.11 42% 270.02 218.00 24% % Earnings before interest tax and deprecation 29% 25% 4% 26% 24% 2% Other income /(expenses) 5.00 2.84 76
”) increased by 21% yoy and 27% yoy, respectively. In light of non-social security revenue, the Company posted 13% growth in 2017 and 8% in 4Q17 which was attributable to the increase of number of patients and
of hospital operations 257.36 226.88 13% Gross margin 125.57 86.97 44% % Gross margin 33% 28% 5% Administrative expenses 47.84 35.48 35% Earnings before interest, taxes and depreciation 105.66 75.92 39
earnings (EBITDA). Shareholders, including the majority shareholders, expressed their faith in the performance and future prospects of the Company and subscribed, in large numbers, to the warrants (IVL-W1
earnings (EBITDA). Shareholders, including the majority shareholders, expressed their faith in the performance and future prospects of the Company and subscribed, in large numbers, to the warrants (IVL-W1
meet market demand in 3Q17. Therefore, the tailwinds in volume and margins are expected to handsomely beat earnings estimates on a fully diluted basis following the exercise of W1 warrants. 3 In last
achieved strong earnings, a growth of 49% in core EBIDTA or $749 mil- lion which is on track to deliver over $1 Billion in annual EBITDA in 2017, the first time in the history of the Company. The strong
= 18.48 percent (the shareholder holding is diluted by 18.48 percent) 3.3 Earnings per Share Dilution Earnings per share dilution can be calculated by using a formula as follows; Earnings per Share Dilution
3,522,000,000 = 18.48 percent (the shareholder holding is diluted by 18.48 percent) 3.3 Earnings per Share Dilution Earnings per share dilution can be calculated by using a formula as follows; Earnings per Share
million (THB 8.4 billion), -7% YoY, Core EBITDA margin 10% Core Net profit after tax of $128 million (THB 4.0 billion), -27% YoY Core Earnings Per Share of THB 0.67, -32% YoY Operating Cash Flow of